Literature DB >> 3517077

Pharmacokinetics of captopril in elderly healthy male volunteers.

W A Creasey, P T Funke, D N McKinstry, A A Sugerman.   

Abstract

The pharmacokinetics of captopril were studied in 12 healthy male volunteers aged 65 to 76 years, who each received a single 100-mg oral dose. Blood and urine samples were collected over a 24-hour period, and assayed for unchanged captopril (CAP), S-methylcaptopril (Me-CAP, plasma concentrations from 2 subjects only), and total captopril levels (TOT, a mixture of CAP and its dimer and mixed disulfides with endogenous thiol-containing compounds such as glutathione and cysteine). Mean values for the maximum concentration (Cmax) were 803 and 66.3 ng/mL for CAP and Me-CAP, respectively. Mean time to maximum concentration (tmax) was determined as 1.0, 1.4, and 1.0 for CAP, TOT, and Me-CAP, respectively. Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr). The mean estimated half-life (t 1/2) for CAP was 1.4 hr, and its renal clearance was 187 mL/hr/kg. Mean urinary excretion over 24 hr was 20.8 and 53.1 for CAP and TOT, respectively. Cmax, and AUC for CAP were 9% less and 13% greater, respectively, than in a historical control group of 18-35-year-old men, treated in the same clinic, by the same personnel, using the same analytic procedures, whereas the 24-hour urinary excretion was 25% lower and eight-hour renal clearance 36% lower in the older population. Since the values for Cmax, AUC, and t 1/2 were similar in the two populations, it does not appear that the pharmacokinetics of CAP are altered markedly with age alone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517077     DOI: 10.1002/j.1552-4604.1986.tb03521.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Optimal dosage of ACE inhibitors in older patients.

Authors:  B Tomlinson
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 3.  Ontogeny of drug elimination by the human kidney.

Authors:  Nancy Chen; Katarina Aleksa; Cindy Woodland; Michael Rieder; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2005-12-06       Impact factor: 3.714

4.  A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 5.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

6.  Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.

Authors:  G Kaiser; R Ackermann; W Dieterle; C J Durnin; J McEwen; K Ghose; A Richens; I B Holmes
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

9.  Effects of the reactive oxygen species hypochlorous acid and hydrogen peroxide on force production and calcium sensitivity of rat cardiac myofilaments.

Authors:  N G MacFarlane; D J Miller
Journal:  Pflugers Arch       Date:  1994-10       Impact factor: 3.657

Review 10.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.